Regulation FD Disclosure Form 8 K

Item 7.01 Regulation FD Disclosure.

Rani Therapeutics Holdings, Inc. (the "Company"), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it had recently engaged in discussions with various investors to explore a potential equity financing. After evaluating ongoing business development discussions and financing opportunities and its cash position, business outlook and market conditions, the Company has elected not to move forward with an equity financing at this time. The Company will continue to evaluate its cash needs and business outlook, and it may seek additional equity financing in the future. All of the information furnished in this Item 7.01 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.